Concepts (69)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 10 | 2022 | 91 | 2.010 |
Why?
|
| Hepatitis, Alcoholic | 6 | 2022 | 8 | 1.470 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 7 | 0.700 |
Why?
|
| Waiting Lists | 3 | 2019 | 16 | 0.420 |
Why?
|
| Alcohol Drinking | 4 | 2020 | 66 | 0.360 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 4 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 25 | 0.350 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 103 | 0.320 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2022 | 31 | 0.320 |
Why?
|
| Liver Cirrhosis | 3 | 2022 | 42 | 0.250 |
Why?
|
| Alcohol Abstinence | 3 | 2020 | 4 | 0.230 |
Why?
|
| Humans | 14 | 2022 | 22592 | 0.210 |
Why?
|
| Middle Aged | 8 | 2021 | 7800 | 0.200 |
Why?
|
| Biopsy | 2 | 2021 | 188 | 0.200 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 7 | 0.200 |
Why?
|
| Liver | 2 | 2021 | 136 | 0.190 |
Why?
|
| Female | 10 | 2021 | 12734 | 0.180 |
Why?
|
| Alcoholism | 1 | 2022 | 62 | 0.180 |
Why?
|
| Living Donors | 1 | 2020 | 16 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2019 | 300 | 0.160 |
Why?
|
| Consensus | 1 | 2020 | 81 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 5 | 0.150 |
Why?
|
| Clinical Coding | 1 | 2019 | 5 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 11 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 28 | 0.150 |
Why?
|
| Time Factors | 4 | 2019 | 1247 | 0.150 |
Why?
|
| Hemochromatosis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 2 | 0.140 |
Why?
|
| Nitriles | 1 | 2017 | 13 | 0.140 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 9 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 29 | 0.130 |
Why?
|
| Models, Biological | 1 | 2019 | 300 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 83 | 0.130 |
Why?
|
| Patient Selection | 1 | 2018 | 167 | 0.130 |
Why?
|
| Adult | 6 | 2019 | 6826 | 0.120 |
Why?
|
| Recurrence | 3 | 2022 | 270 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2019 | 1386 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2019 | 2915 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2954 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 104 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 375 | 0.100 |
Why?
|
| Male | 7 | 2019 | 12260 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 104 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 804 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2019 | 227 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2012 | 43 | 0.090 |
Why?
|
| Aged | 5 | 2017 | 7300 | 0.090 |
Why?
|
| Ethiodized Oil | 1 | 2011 | 1 | 0.090 |
Why?
|
| Survival Rate | 1 | 2011 | 302 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2019 | 537 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 1607 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 350 | 0.060 |
Why?
|
| Graft Survival | 2 | 2014 | 84 | 0.050 |
Why?
|
| United States | 2 | 2019 | 1741 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 22 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 22 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 58 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2019 | 22 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 28 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 26 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 344 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 623 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 618 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 800 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1476 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1403 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 1955 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 517 | 0.020 |
Why?
|